טוען...
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
BACKGROUND: Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS. METHODS: We partitioned OS into two...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4137232/ https://ncbi.nlm.nih.gov/pubmed/19903805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djp369 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|